• Mashup Score: 0

    Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

    Tweet Tweets with this article
    • Annualized healthcare costs for the 24-month study period were highest among patients with both #NASH and #T2D, with investigators further highlighting the incremental cost of developing comorbid NASH or T2D. Learn more: https://t.co/F0yAtsTCqb

  • Mashup Score: 0

    Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the commonest causes of liver-related mortality and morbidity, with a predicted global prevalence of 30%.1 This finding has fuelled extensive therapeutic research; however, there are no currently licensed therapies for NAFLD, with weight loss and lifestyle interventions as the mainstay of treatment.

    Tweet Tweets with this article
    • Linked Comment - Sara Mahgoub & Phil Newsome - Efruxifermin in non-alcoholic steatohepatitis https://t.co/XwqA1W4hMX #LiverTwitter #NASH #MASH @phil_newsome7

  • Mashup Score: 0

    Investigators developed the identification model based on significantly associated factors of fibrotic NASH and tested it in derivation and validation cohorts, where it identified 89.9% and 81.0% of patients with fibrotic NASH, respectively.

    Tweet Tweets with this article
    • A composite score of alanine aminotransferase, BMI, diabetes, and age, the ABDA score may be a viable screening tool for #NASH, offering a new noninvasive score for fibrosis. Learn more: https://t.co/TTnqU7w0cJ

  • Mashup Score: 1
    Home - 7 month(s) ago

    The incidence of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), continues to rise globally along with an increase in obesity, type 2 diabetes, and other metabolic disorders. Patients at risk of MASH greatly benefit from early identification and intervention. Join us at this interactive, case-based symposium where you can see how your case management strategies compare with those of your peers. Don’ t miss out! This activity is intended for

    Tweet Tweets with this article
    • 📣 DON’T MISS: Evaluating risk of #fibrotic disease and #NASH in patients with risk factors. Join experts November 12 by clicking the link here: https://t.co/55Kc0cvwdK #MedEd #Medtwitter https://t.co/ZzUvm0EC63